Diagnostic Test for Inflammatory Bowel Diseases

Technology #31169

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Depiction of the hypothesis for UC disease progression and its relationship with polyamines, according to an embodiment of the present invention
Categories
Researchers
Otto Phanstiel, Ph.D.
Managed By
Brion Berman
Sr. Licensing Associate 407.882.0342
Patent Protection

Diagnostic tests for inflammatory bowel diseases

US Patent 7,972,807 B1

Inflammatory bowel disease (IBD) is an autoimmune disorder resulting in the inflammation of the intestinal tissue. It is grouped into two types: ulcerative colitis (UC), which affects the mucosal lining of the large intestine; and Crohn’s disease (CD), which affects the entire intestine. IBD patients also have an increased risk of developing colon cancer. Diagnosing IBD is difficult, especially when the tissue does not appear to be inflamed upon examination. To assist in diagnosis, University of Central Florida researchers have developed a novel test involving polyamines.

Technical Details

This technology demonstrates a correlation between high levels of polyamines and the presence of IBD. This technology can be developed into a diagnostic test for early detection of IBD. The test would use a small amount of blood, instead of the traditional tissue biopsy, to detect IBD and may potentially prevent its progression into colon cancer.

Benefits

  • Early detection of IBD
  • Less invasive testing

Application

  • Diagnostic test to detect IBD